Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) CEO Claire Mazumdar sold 1,596 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $18.95, for a total transaction of $30,244.20. Following the completion of the transaction, the chief executive officer directly owned […]

Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) CEO Claire Mazumdar sold 6,499 shares of the business’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $18.84, for a total transaction of $122,441.16. Following the completion of the sale, the chief executive officer owned 339,392 […]

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) CMO Harold Bernstein sold 15,000 shares of the stock in a transaction on Friday, March 20th. The stock was sold at an average price of $49.10, for a total transaction of $736,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which […]

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) COO Jeremy Chadwick sold 25,758 shares of Kymera Therapeutics stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $83.30, for a total value of $2,145,641.40. Following the transaction, the chief operating officer owned 68,052 shares of the company’s stock, […]